Nachrichten zur Eli Lilly & Co. Aktie

Hims & Hers Health (HIMS) Is Up 19.4% After Expanding GLP-1 Access Via LillyDirect Integration

Earlier this week, Hims & Hers Health said clinicians on its platform can now prescribe Eli Lilly GLP-1 weight loss…

Hims & Hers (HIMS) Stock Jumps 7% After Expanding Eli Lilly GLP-1 Deal

Hims & Hers (HIMS) stock rose 7% after expanding its Eli Lilly deal, adding Zepbound prescriptions to its GLP-1 platform…

Hims Stock Drops on LillyDirect Deal. Can It Be the Netflix of Pharma?

Hims & Hers Health will allow providers to prescribe scripts filled by LillyDirect, Eli Lilly’s direct-to-consumer platform.…

Hims Yields Ground in GLP-1 Market. Why Its CEO Is Calling It the Netflix of Pharma.

Hims & Hers Health will allow providers to prescribe scripts filled by LillyDirect, Eli Lilly’s direct-to-consumer platform.…

Hims Stock Falls as It Pivots From GLP-1 Compounding. Why the ‘Netflix’ Argument Is Failing.

Hims & Hers Health will allow providers to prescribe scripts filled by LillyDirect, Eli Lilly’s direct-to-consumer platform.…

Hims & Hers jumps 7% after expanding partnership with Eli Lilly

Hims & Hers Health (NYSE:HIMS) shares climbed 7% after the company revealed an expansion of its platform that allows healthcare…

Hims rises after it says it now offers “full range” of FDA-approved GLP-1s

Hims providers can now send prescriptions to Eli Lilly’s direct-to-consumer pharmacy....…

Why One Analyst Is Dubious On Hims Newest Obesity Plan

Hims stock reversed lower Thursday despite new efforts in weight loss that connect patients with Eli Lillys self-pay pricing.…

Hims & Hers adds Lilly GLP-1 treatments to lineup – CEO compares it to Netflix’s early days

?Hims & Hers CEO Andrew Dudum noted that, like Netflix gave users the choice of what they wanted most, Hims…

Why Hims & Hers stock surged 7% in a single trading day

Hims & Hers Health stock jumped 7% after expanding its platform to include Eli Lillys GLP-1 weight loss medications. Heres…

Hims & Hers stock surges 7% on Eli Lilly partnership expansion

Hims & Hers stock surges 7% on Eli Lilly partnership expansion…

Eli Lilly’s Kelonia Therapeutics acquisition seen as strategic bet on next-generation CAR-T: analysts

Eli Lilly and Co (NYSE:LLY)’s acquisition of Kelonia Therapeutics is being seen as a positive step for long-term pipeline building,…

LLY to Buy Oncology Biotech Kelonia Therapeutics for $7 Billion

Eli Lilly is set to acquire Kelonia Therapeutics in a $7B deal, boosting its genetic medicine platform with a novel…

Eli Lilly: Wachstumsstark, strategisch klug und nach Rücksetzer attraktiv!

Die Aktie von Eli Lilly (NYSE: LLY) bleibt aus meiner Sicht ein hochwertiger Wachstumswert mit attraktiven Chance-Risiko-Profil. Mit einem Forward-KGV…

Eli Lilly: We Havent Reached Its Peak Yet (Rating Upgrade)

…

Eli Lilly taps into its GLP-1 windfall, while Honeywell sheds a lower-margin unit

Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of…

Eli Lilly: 2 Mrd. USD für die Zukunft der Krebsmedizin!

Eli Lilly (NYSE: LLY) steht kurz vor der Übernahme von Kelonia Therapeutics für mehr als 2 Mrd. USD. Ein bemerkenswerter…

Will Eli Lillys New GLP-1 Pill Get the Stock Get Back to a $1 Trillion Valuation?

Regulators approved the companys GLP-1 weight loss pill, Foundayo, at the beginning of April.…

Eli Lilly agrees to acquire cancer drug maker Kelonia in deal worth up to $7 billion

Kelonia is developing technology to reprogram patients T-cells inside the body so those cells can attack cancer, called in vivo…

Eli Lilly expands genetic medicine capabilities with Kelonia Therapeutics acquisition

Eli Lilly and Co (NYSE:LLY) has agreed to acquire private clinical-stage biotechnology firm Kelonia Therapeutics in a deal aimed at…

Eli Lilly in advanced talks to acquire Kelonia Therapeutics for over $2 billion, WSJ says

A deal could be reached as soon as Monday and could include additional payments tied to Kelonia meeting certain milestones,…

Eli Lilly in advanced talks to acquire Kelonia Therapeutics for over $2 billion, WSJ says

Eli Lilly in advanced talks to acquire Kelonia Therapeutics for over $2 billion, WSJ says…

This Drug Stock Has Crushed the S&P 500 Over the Last Decade

Eli Lilly is leading the GLP-1 charge, but investors have already priced much of the good news into the stock.…

Truist reiterates Eli Lilly stock rating on positive trial data

Truist reiterates Eli Lilly stock rating on positive trial data…

Eli Lillys Oral Drug Clears CV Test, Hims Surges 14%

Eli Lillys oral obesity drug Foundayo passed cardiovascular safety testing while Hims & Hers surged 14% after the FDA scheduled…

Is This $6.3 Billion Deal a Game Changer for Eli Lilly?

Its acquiring an asset with a very promising lead drug candidate.…

Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know

Eli Lilly (LLY) concluded the recent trading session at $905.03, signifying a -1.89% move from its prior days close.…

The $1 Trillion Race: Why Eli Lilly Is Leaving Novo Nordisk in the Dust

And can Novo Nordisk catch up to its rival in the weight loss market?…

Lilly investing billions to prepare for overseas oral GLP-1 launches

With many overseas patients preferring orals to injectables, Eli Lilly has filed for approval of orforglipron in more than 40…

Top Stock Reports for Eli Lilly, Mastercard & AMD

Eli Lilly rides strong GLP-1 demand and pipeline momentum, while Mastercard and AMD navigate mixed performance and rising competition pressures.…

Leerink reiterates Eli Lilly stock rating on positive trial data

Leerink reiterates Eli Lilly stock rating on positive trial data…

Eli Lilly Isnt Replacing Zepbound -- Its Building an Obesity Empire

And its not too late to get in on the action.…

Hims And Hers Confronts Amazon Threat While Advancing AI Weight Loss Plan

Amazon Pharmacy has entered the weight loss medication market with Eli Lilly’s new GLP-1 drug, offering same day delivery and…

Eli Lilly: Warum Foundayo die Marktführerschaft im Adipositas-Sektor zementiert

Der Markt für Adipositas-Behandlungen erlebt derzeit eine fundamentale Verschiebung, und Eli Lilly positioniert sich mit der breiten Markteinführung seiner Abnehm-Pille…

Eli Lilly market share drops, Novo Nordisk holds firm as generic weight-loss drugs flood India

Eli Lilly loses share in India’s GLP?1 market as cheap semaglutide generics surge, while Novo holds steady after deep price…

Amazon to stock Lillys new weight-loss pill at US kiosks, offer same-day delivery

Amazon.com said on Thursday its pharmacy unit will stock Eli Lillys new weight-loss pill at kiosks located at some of…

New weight-loss pill wins FDA approval as demand surges

Eli Lilly, the pharmaceutical giant, secured an important victory in the intensifying war against diabetes and obesity. Earlier this month,…

Eli Lilly (LLY) Ascends But Remains Behind Market: Some Facts to Note

In the most recent trading session, Eli Lilly (LLY) closed at $953.3, indicating a +2.39% shift from the previous trading…

Is Eli Lilly Stock a Buy After a Brand New Approval?

The stocks dip might be an opportunity.…

Pharma, Biotech Giants Ramp Up M&A in Q1 to Boost Pipelines

Eli Lilly and peers like Novartis fuel a 2026 pharma M&A surge, striking billion-dollar deals to expand pipelines, tap AI…

Eli Lillys One-Two Punch Could Knock Novo Nordisk Out of the Obesity Drug Fight

The U.S. Food & Drug Administration just approved Eli Lillys GLP-1 pill orforglipron.…

Eli Lilly (LLY) Stock Sinks As Market Gains: Heres Why

In the most recent trading session, Eli Lilly (LLY) closed at $935.58, indicating a -1.98% shift from the previous trading…

Bank of America sees Eli Lilly’s Foundayo as preferred oral GLP-1

Eli Lilly and Co (NYSE:LLY) is entering the US market slightly ahead of schedule with its oral GLP-1 weight-loss therapy…

Zulassung von Lillys Adipositas-Pille eröffnet neue Front im Abnehmkrieg

Die Pille des Pharmariesen wird auf dem boomenden, milliardenschweren Markt für Adipositas-Medikamente gegen einen Rivalen von Novo Nordisk antreten. Der…

Novo Nordisk says Wegovy pill outperforms Lilly’s oral GLP-1 in cross-trial comparison

Novo and Eli Lilly are both trying to shape the narrative of their rival pills, considered to be the start…

Wall Street sees multi-billion dollar debut for Lillys obesity pill despite Novo lead

Eli Lillys newly approved weight-loss pill is expected to generate billions in sales as soon as this year, with analysts…

Novo VP Weighs In on Approval of Lilly’s Obesity Pill

Jamey Millar, executive vice president, US operations of Novo Nordisk, reacts to Eli Lilly’s once-daily weight-loss pill, called Foundayo, winning…

Novo’s New US Chief on Lilly’s Rival Weight-Loss Pill

Novo Nordisk Executive Vice President for US Operations Jamey Millar discusses the US approval of competitor Eli Lillys obesity pill,…

AKTIE IM FOKUS: Eli Lilly ziehen weiter an - Diätpille in den USA zugelassen

NEW YORK (dpa-AFX) - Nach der Zulassung der Diätpille von Eli Lilly in den USA…

Eli Lilly opposes push to pass Trumps drug pricing deals into law, CEO says

Eli Lilly opposes the White Houses push to codify "most favored nation" drug pricing into law, CEO Dave Ricks said…